Author's response to reviews

Title: Long-term effect of three Tiao-Bu Fei-Shen therapies on NF-kappaB/TGF-beta1/smads signaling in rats with chronic obstructive pulmonary disease

Authors:

Ya Li (yuanfengtcm@126.com)
Jiansheng Li (li_is8@163.com)
Weiwei Li (13526736192@139.com)
Suyun Li (lisuyun2000@126.com)
Yange Tian (yange0910@126.com)
Xiaofan Lu (fannaleo.09010322@163.com)
Suli Jiang (jiangsuli1007@163.com)
Ying Wang (yinghuafei0001@126.com)

Version: 5
Date: 27 November 2013

Author's response to reviews: see over
Dear editor

Thank you for your useful suggestions on our manuscript. We’re sorry we have ignored some details when submitting the manuscripts. We have modified the manuscript and added the content as you mentioned. The detailed corrections are listed below point by point.

1 Please include Competing Interests, and Authors' Contributions sections in your manuscript. Information on these can be found on the link provided.

We are so sorry to ignore these important contents. We have added it in the manuscript as follows:

Competing interests
The authors declare that they have no competing interests and they don’t receive any funding by Pharmaceutical factory.

Authors' Contributions
LY, LJS and LSY contributed to the study design. LY also contributed to data analysis, manuscript drafting and process control with LSY. LWW contributed to protein analysis and data collection. TYG and LXF contributed to RNA analysis and data collection. JSL and WY contributed to animal experiment and cytokines analysis. All authors had read and approved the final manuscripts.

2 Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines and where available should have been approved by an appropriate ethics committee. A statement detailing compliance with guidelines and/or ethical approval must be included in the manuscript.

Experimental protocols were approved by the Experimental Animal Care and Ethics Committees of the First Affiliated Hospital, Henan University of Traditional Chinese Medicine.

3 Please provide more information in your manuscript on source and exact constitution of the three therapies used in your study. This information should be sufficient to allow other researchers to repeat your studies, if so wish.

Thank you for your reminding. We are very glad to provide the information about the three therapies.

Bufei Jianpi granules for lung-spleen qi deficiency were mainly composed of Huang Qi (Astragalus
propinquus), Dang Shen (Codonopsis pilosula), Bai Zhu (Atractylodes macrocephala), Fu Ling (Wolfiporia extensa). Bufei Yishen granules for lung-kidney qi deficiency were mainly composed of Ren Shen (Radix Ginseng), Huang Qi (Astragalus propinquus), Shan Zhu Yu (Fructus Corni), and Yin Yang Huo (Herba Epimedii). Yiqi Zishen granule for lung-kidney qi and yin deficiency were mainly composed of Ren Shen (Radix Ginseng), Huang Jing (Polygonatum sibiricum), Shu Di Huang (Rehmannia glutinosa), Mai Dong (Ophiopogon japonicus). The granules were prepared into fluidextractum according to the standard operating procedure established by Department of Pharmaceutics, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine.

This point has been added in the manuscript.

Sincerely,

Ya Li